Novartis’ pelacarsen cuts Lp(a) 78% but fails cardiovascular trial

Pelacarsen reduced lipoprotein(a) (Lp(a)) by 78% in a Phase III trial of more than 8,300 adults yet produced no reduction in major adverse cardiovascular events, raising questions about whether lowering Lp(a) reduces them.

A long bridge extends from one cliff almost to the other but stops just short, leaving a small unbridged gap above a deep chasm, with tiny silhouettes waiting at the edge.

CLINICAL CATALYST · PHASE III TRIAL DATA · NOVEMBER 17, 2026 · GLOBAL

Seven years and more than 8,300 patients later, a closely watched cardiovascular trial produced a result that the study’s senior author, Steven E. Nissen, M.D., called ‘unexpected and surprising’: pelacarsen, a lipoprotein(a) (Lp(a))-lowering drug developed by Novartis and Ionis Pharmaceuticals, reduced Lp(a) levels by a mean of 78% — and did nothing to reduce the risk of heart attacks, strokes, urgent revascularization procedures, or cardiovascular death.

The primary results of the Lp(a) HORIZON trial, a Phase III, multicenter, international study enrolling adults with established cardiovascular disease (CVD) and Lp(a) levels at or above 70 mg/dL in 42 countries, were presented on November 7, 2026, at the American Heart Association’s (AHA) Scientific Sessions 2026 in Chicago and simultaneously published in The New England Journal of Medicine and NEJM Evidence, according to the AHA newsroom.

78%

Pelacarsen reduced Lp(a) levels by a mean of 78% across all participant groups in the Phase III Lp(a) HORIZON trial, yet produced no change in major adverse cardiovascular events, per the American Heart Association.

‘I cannot avoid the disappointing conclusion – it didn’t work. Pelacarsen improved Lp(a) measures significantly – 78% lower; however, cardiovascular outcomes were unchanged. The neutral finding was unexpected and surprising to the medical community,’ said Steven E. Nissen, M.D., senior author of the study and chief academic officer of the Miller Family Heart, Vascular & Thoracic Institute at the Cleveland Clinic, in the AHA statement.

A biomarker without a mechanism

At enrollment, participants received 30-90 days of treatment for CVD risk factors if needed to meet current guidelines for cholesterol and blood pressure (about 75% already met them), then received either pelacarsen or placebo as a monthly subcutaneous injection, with Lp(a) measured annually. The primary composite outcome — time to first occurrence of nonfatal heart attack, stroke, urgent revascularization, or death from any cardiovascular cause — was neutral. So was every secondary endpoint and every subgroup analysis, including the trial’s second primary analysis, in patients with Lp(a) at or above 90 mg/dL, representing the highest 15% of people worldwide with elevated Lp(a), per the AHA statement.

‘The results were completely neutral across multiple analyses. There was basically no effect on outcomes, not even a trend, even in subpopulations,’ Nissen said in the AHA statement. He was careful, however, to separate the trial’s failure from a verdict on the target itself: ‘[T]his does not mean Lp(a) is irrelevant. It means we need more in-depth research to help us fully understand the underlying mechanisms of Lp(a), its interactions with other CVD risk factors and how it does or does not impact cardiovascular outcomes.’

That distinction matters for the broader field. Lp(a) — a fatty, cholesterol-carrying protein particle — has been linked to CVD through decades of genetic and epidemiological research. According to the AHA, high Lp(a) (125 nmol/L or greater, or 55 mg/dL or higher) is associated with approximately a 1.4-fold increased long-term risk of heart attack or stroke, and an Lp(a) of 250 nmol/L (or 115 mg/dL) is associated with at least a two-fold increased long-term risk. Lp(a) levels are largely genetically determined and remain relatively stable over a lifetime; lifestyle changes and statins have little impact on them. The AHA statement notes that there is currently no FDA-approved medication to lower Lp(a).

The HORIZON result does not disprove that association. It demonstrates that lowering Lp(a) pharmacologically — at least with this molecule, in this population, on this background therapy — does not translate that epidemiological signal into clinical benefit. Whether the failure reflects the mechanism of pelacarsen specifically, the threshold chosen for enrollment, the duration of treatment, or a more fundamental limit of the Lp(a) hypothesis remains, on the available evidence, unresolved.

Pipeline exposure for Amgen and Eli Lilly

The commercial stakes are substantial. Reuters reported in September 2026 that analysts had estimated pelacarsen’s peak annual sales at between $3 billion and $6 billion — a range that now requires reassessment. Investors had been counting on pelacarsen, the anti-inflammatory drug remibrutinib and the RNA therapy del-desiran to drive growth as Novartis faces patent expiries on older blockbusters, including the heart drug Entresto (sacubitril/valsartan), according to the same Reuters report. Entresto sales fell 42% to $1.31 billion in the first quarter of 2026 after US patents expired, per Reuters.

The HORIZON result also raises the scrutiny on competing Lp(a)-lowering programs. Amgen and Eli Lilly are each running late-stage trials of siRNA (small interfering RNA) Lp(a)-lowering drugs — olpasiran and lepodisiran, respectively — according to Reuters reporting from September 2026. The mechanism of action differs from pelacarsen’s antisense oligonucleotide approach, but the outcome question is the same: does lowering Lp(a) reduce cardiovascular events? HORIZON provides the first large-scale Phase III answer, and it is neutral.

Novartis CEO Vas Narasimhan, speaking on the company’s third-quarter earnings call on October 27, 2026, maintained the company’s 5% to 6% annual compounded growth target between 2025 and 2030, and mid-single-digit long-term growth over a 10-year timeframe, according to FiercePharma. His near-term confidence rests partly on remibrutinib (Rhapsido), a Bruton’s tyrosine kinase (BTK) inhibitor approved for two forms of chronic hives — chronic spontaneous urticaria and symptomatic dermographism — for which Novartis raised its peak sales projection in those two chronic hives indications to $4 billion from $3 billion previously, and is targeting an additional $4 billion from relapsing multiple sclerosis following positive Phase III results, per FiercePharma. ‘We’ve done all the modeling. We feel very comfortable with those numbers,’ Narasimhan said, per FiercePharma’s October 2026 report. FiercePharma described pelacarsen and del-desiran as “two late-stage clinical failures of high-value projects.”

Novartis’ Chief Medical Officer Shreeram Aradhye said in a September 2026 statement, as reported by BioPharma Dive, that the results ‘are not the results we hoped for’ but could ‘help inform future approaches to cardiovascular management.’

One structural complication for the competing programs is that HORIZON’s neutrality is not easily attributed to a design flaw that rivals can correct. The trial enrolled more than 8,300 participants, ran for seven years, achieved a 78% mean reduction in Lp(a), and tested the hypothesis in the subgroup with the highest Lp(a) burden. If the result reflects a genuine limit of the target rather than a molecule-specific or design-specific failure, Amgen’s olpasiran and Eli Lilly’s lepodisiran face the same outcome question regardless of their differing mechanisms. Some analysts cited by Reuters counter that the rival drugs lowered Lp(a) more effectively in earlier studies and are being tested in patients with especially high Lp(a). That reading remains untested — the trials have not reported — and HORIZON’s neutral result in the ≥90 mg/dL subgroup weakens it.

Novartis registered an open-label extension (OLE) study, NCT07517263, to evaluate the long-term safety and tolerability of pelacarsen in participants who completed the parent Lp(a) HORIZON trial, according to the ClinicalTrials.gov record. The OLE, sponsored by Novartis Pharmaceuticals, listed an estimated enrollment of 5,700 participants; the record’s own summary states the study ‘has been terminated by sponsor following the outcome of the Lp(a)HORIZON study’, although its status field still read ‘Active, not recruiting’ on November 13, 2026.

For patients with high Lp(a), the HORIZON result leaves the clinical picture unchanged in one respect: the trial’s researchers, in the AHA release, urge everyone to have their Lp(a) levels measured to help estimate CVD risk, even in the absence of an approved therapy. Nissen’s statement in the AHA release is direct: ‘Measuring Lp(a) is still absolutely worthwhile. Lp(a) is an important risk factor for CVD, and high levels of Lp(a) usually do not present with any symptoms.’

What to Watch

  1. Phase III cardiovascular outcome readouts from Amgen’s olpasiran and Eli Lilly’s lepodisiran programs, which will determine whether HORIZON’s neutral result is molecule-specific or class-wide
  2. Further analyses of the Lp(a) HORIZON dataset published in The New England Journal of Medicine and NEJM Evidence, which may clarify subgroup patterns and inform the design of future trials
  3. Novartis’ pipeline reconfiguration following two late-stage failures — pelacarsen and del-desiran — and whether analysts revise the more than $10 billion in combined peak-sales potential they attributed in July 2026, per Reuters, to three late-stage drugs
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper asymmetry in this result is epidemiological: the same genetic and population data that built the Lp(a) hypothesis over decades could not be converted into a clinical outcome by the first completed Phase III outcomes trial of an Lp(a)-lowering drug. That gap — between a risk factor’s association with disease and its amenability to pharmacological intervention — is not unique to Lp(a), but HORIZON makes it visible at a scale that could shape how the cardiovascular field designs, funds, and prices the next generation of biomarker-targeted therapies.

Lp(a) HORIZON Phase III Trial · Global Enrollment and Duration

Parameter Value
Participants enrolled More than 8,300 adults
Countries 42
Trial duration 7 years
Primary Lp(a) enrollment threshold ≥70 mg/dL
Second primary analysis threshold ≥90 mg/dL (top 15% worldwide)
Mean Lp(a) reduction 78%

Source: AHA newsroom, Lp(a) HORIZON trial primary results

Why this is relevant

Patients

The Lp(a) HORIZON trial’s neutral result leaves people with high Lp(a) without a proven pharmacological option. The trial’s researchers continue to urge Lp(a) testing for cardiovascular risk assessment, as Lp(a) of 250 nmol/L (115 mg/dL) is associated with at least a two-fold increased long-term risk of heart attack or stroke, per the AHA statement.

Industry

Novartis and Ionis Pharmaceuticals lose a candidate analysts estimated at $3 billion–$6 billion in peak annual sales. The result may suggest that Amgen’s olpasiran and Eli Lilly’s lepodisiran, both in Phase III, face the same unresolved outcome question regardless of their differing mechanisms, raising the possibility of class-wide revaluation before those trials report.

Payers

A neutral Phase III outcome removes any near-term formulary obligation for an Lp(a)-lowering drug class. Payers and pharmacy benefit managers face no immediate coverage decision, though the competing programs from Amgen and Eli Lilly could reopen that question if their outcome data diverge from HORIZON’s result.

Regulators

The FDA has no approved Lp(a)-lowering therapy, per the AHA statement. The HORIZON dataset — seven years, more than 8,300 participants, 42 countries — could inform regulatory expectations for outcome evidence in future Lp(a) program submissions, particularly regarding the relationship between biomarker reduction and clinical endpoints.

Sources: American Heart Association: Lp(a) HORIZON trial — Lp(a) fell by 78%, but cardiovascular outcomes unexpectedly neutral · ClinicalTrials.gov: NCT07517263 — An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) · BioPharma Dive: Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines · FiercePharma: Novartis CEO unfazed by high-profile clinical failures, maintains long-term revenue goal · Reuters: Novartis cholesterol setback tests hopes for emerging heart disease drugs · Reuters: Novartis posts earnings miss as generic rivals hurt blockbuster drug Entresto · Veeva Clinical Trials: An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) · Reuters via Euronext: Novartis faces drug pipeline test with valuation premium in focus

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related